Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358793 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1711406 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL25887054 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL18261644 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL31438645 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16648146 | 1.00 | DPP4 (0.55) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL16053901 | 0.98 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30457093 | 0.96 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29871436 | 0.96 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30463284 | 0.96 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007762-A1 | ANTI-ROR2 ANTIBODY-DRUG CONJUGATES | SOLVE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| US-20250242040-A1 | ALBUMIN CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou KangDeRui Pharmaceutical, Ltd. (CN) | 2025-07-31 | — | — | US | claimed |
| WO-2025129098-A1 | TYROSINASE-BASED CONJUGATE COMPOSITIONS AND METHODS OF USE | CATENA BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025059190-A2 | POLYPEPTIDE CONJUGATION COMPOSITIONS AND METHODS OF USE | CATENA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | claimed |
| EP-4096717-B1 | TREATMENT OF CANCER | INNATE PHARMA (FR) | 2024-12-11 | — | — | EP | claimed |
| CN-118892553-A | Esatitecan analogue, ligand-drug conjugate thereof and application thereof | 浙江大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118829450-A | Eptification derivative-antibody conjugate and medical application thereof | 甘李药业股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| WO-2024179536-A1 | ALBUMIN CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 刘成杰 | 2024-09-06 | — | — | WO | claimed |
| CN-118580336-A | Albumin conjugate and preparation method and application thereof | 刘成杰 | 2024-09-03 | — | — | CN | claimed |
| EP-3972647-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-03-30 | — | — | EP | claimed |
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | claimed |
| EP-3525826-B1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS BV (NL) | 2020-07-22 | — | — | EP | claimed |
| EP-3525826-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | Synthon Biopharmaceuticals B.V. (NL) | 2019-08-21 | — | — | EP | claimed |
| WO-2018069375-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-04-19 | — | — | WO | claimed |
| CN-1036832-C | Composition containing a penem or carbapenem artibiotic and the use of the same | SANKYO CO (JP) | 1997-12-31 | — | — | CN | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| CN-86107574-A | Compositions containing penem or carbapenem antibiotics and their use | — | 1987-05-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | DPP4 1007/4885DPP8 1375/4885DPP9 950/4885 |
| US-20250242040-A1 | ALBUMIN CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | ALB, GOT1, ASGR1 | DPP4 2034/4885DPP8 1140/4885DPP9 2597/4885 |
| US-20260007762-A1 | ANTI-ROR2 ANTIBODY-DRUG CONJUGATES | RORB, RORA, RORC | DPP4 4453/4885DPP8 3958/4885DPP9 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.